Audio is streamed directly from the publisher (mcdn.podbean.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
One of the challenges of treating brain tumors is delivering potent biologic therapies across the blood-brain barrier. Adaptin Bio has developed platform technology that harnesses a patient’s own T cells to transport bispecific therapeutic payloads across the blood-brain barrier and into other targeted tissue with an initial focus on treating glioblastoma. We spoke to Michael Roberts, co-founder and CEO of Adaptin Bio, about the unmet need in glioblastoma, the limitations of current blood-brain barrier–crossing strategies, and how the company’s platform seeks to change the treatment paradigm by using patient-derived T cells as delivery vehicles for targeted biologics.